National Institutes of Health (NIH) scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease. The vaccine also generated potentially protective MERS-CoV antibodies in blood drawn from vaccinated camels. A study detailing the synthetic DNA vaccine appears in the Aug. 19 Science Translational Medicine. MERS-CoV, which causes pneumonia deep in the lungs, emerged in 2012 and has sickened more than 1,400 people and killed 500, mostly in the Middle East and Asia.
Led by NIH-funded University of Pennsylvania scientists, the research team developed the investigational MERS vaccine by learning from previous vaccine studies of another coronavirus that causes severe acute respiratory syndrome (SARS). SARS sickened more than 8,000 people and killed more than 700 in 2003. The experimental MERS vaccine uses the S spike protein to generate immunity; because MERS-CoV undergoes mutations, the scientists created a "consensus" S protein by comparing all available MERS-CoV protein sequences. This synthetic protein has shown broad protection against different MERS-CoV types, the scientists report. Collaborators included researchers from NIH's National Institute of Allergy and Infectious Diseases, Division of Intramural Research; Public Health Agency of Canada; Inovio Pharmaceuticals; the University of Washington; and the University of South Florida.
The rhesus macaques received low -or -high doses of the vaccine, although results showed no significant differences between the groups and antibody responses appeared after one or two immunizations regardless of dose. Next, the group plans to explore how to condense the six-week timeframe to establish protection, and they are hopeful the vaccine will become a candidate for use in camels and people.
Source: NIH/National Institute of Allergy and Infectious Diseases
See also: http://www.infectioncontroltoday.com/news/2015/08/synthetic-dna-vaccine-against-mers-induces-immunity.aspx
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.